These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sickle cell disease at the dawn of the molecular era. Abboud MR; Musallam KM Hemoglobin; 2009; 33 Suppl 1():S93-S106. PubMed ID: 20001639 [TBL] [Abstract][Full Text] [Related]
10. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Hsu LL; Champion HC; Campbell-Lee SA; Bivalacqua TJ; Manci EA; Diwan BA; Schimel DM; Cochard AE; Wang X; Schechter AN; Noguchi CT; Gladwin MT Blood; 2007 Apr; 109(7):3088-98. PubMed ID: 17158223 [TBL] [Abstract][Full Text] [Related]
11. An update on arginine in sickle cell disease. Benites BD; Olalla-Saad ST Expert Rev Hematol; 2019 Apr; 12(4):235-244. PubMed ID: 30855194 [TBL] [Abstract][Full Text] [Related]
12. Redox-dependent impairment of vascular function in sickle cell disease. Aslan M; Freeman BA Free Radic Biol Med; 2007 Dec; 43(11):1469-83. PubMed ID: 17964418 [TBL] [Abstract][Full Text] [Related]
13. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Kato GJ; McGowan V; Machado RF; Little JA; Taylor J; Morris CR; Nichols JS; Wang X; Poljakovic M; Morris SM; Gladwin MT Blood; 2006 Mar; 107(6):2279-85. PubMed ID: 16291595 [TBL] [Abstract][Full Text] [Related]
14. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Kaul DK; Zhang X; Dasgupta T; Fabry ME Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H39-47. PubMed ID: 18456737 [TBL] [Abstract][Full Text] [Related]
16. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease. Nader E; Romana M; Connes P Front Immunol; 2020; 11():454. PubMed ID: 32231672 [TBL] [Abstract][Full Text] [Related]
17. Association Between Nitric Oxide, Oxidative Stress, Eryptosis, Red Blood Cell Microparticles, and Vascular Function in Sickle Cell Anemia. Nader E; Romana M; Guillot N; Fort R; Stauffer E; Lemonne N; Garnier Y; Skinner SC; Etienne-Julan M; Robert M; Gauthier A; Cannas G; Antoine-Jonville S; Tressières B; Hardy-Dessources MD; Bertrand Y; Martin C; Renoux C; Joly P; Grau M; Connes P Front Immunol; 2020; 11():551441. PubMed ID: 33250889 [TBL] [Abstract][Full Text] [Related]
18. Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I. Kato GJ Hematology Am Soc Hematol Educ Program; 2008; ():186-92. PubMed ID: 19074079 [TBL] [Abstract][Full Text] [Related]
19. Intravascular hemolysis and the pathophysiology of sickle cell disease. Kato GJ; Steinberg MH; Gladwin MT J Clin Invest; 2017 Mar; 127(3):750-760. PubMed ID: 28248201 [TBL] [Abstract][Full Text] [Related]
20. New strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy. Morris CR Treat Respir Med; 2006; 5(1):31-45. PubMed ID: 16409014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]